Baricitinib for atopic dermatitis patients who responded inadequately to dupilumab treatment: First daily practice results

Baricitinib for atopic dermatitis patients who responded inadequately to dupilumab treatment: First daily practice results

Abstract Background Baricitinib is the first JAK inhibitor registered for the treatment of moderate‐to‐severe atopic dermatitis (AD). Efficacy and safety were shown in clinical trials, but daily practice data is sparse. Objectives To evaluate the effectiveness and safety of baricitinib treatment in...

Full description

Bibliographic Details
Main Authors: Linde deWijs, Corine Schreurs, Anne Schlösser, Tamar Nijsten, Dirk Jan Hijnen
Format: Article
Language:English
Published: Wiley 2022-12-01
Series:JEADV Clinical Practice
Subjects:
atopic dermatitis
baricitinib
dupilumab
immunosuppressive agents
Online Access:https://doi.org/10.1002/jvc2.64

Similar Items

Similar Items